By Michele Missakian, PA-C | Core Function Health

If your cholesterol suddenly increased in your 40s or 50s, even though you haven't made major changes to your diet or lifestyle, there may be more to the story.

The transition through perimenopause and menopause affects much more than periods, hot flashes and sleep.

As ovarian hormones fluctuate and eventually decline, women can experience changes in cholesterol and lipoproteins, body composition, insulin sensitivity and vascular health. All of these can influence long-term cardiovascular risk.

And that matters because cardiovascular disease remains the leading cause of death in women.

Midlife is an important time to start looking deeper.

View this post on Instagram

Why Can Cholesterol Change During Perimenopause and Menopause?

Estrogen has effects throughout the cardiovascular and metabolic systems.

Research following women through the menopause transition has documented changes in lipids and lipoproteins, body composition and vascular health during this stage of life.

This doesn't mean estrogen is the only reason cholesterol changes. Genetics, aging, nutrition, physical activity, sleep, blood pressure, smoking, medications and other medical conditions can all contribute.

But when a woman tells me:

"My cholesterol was always fine. Why did it suddenly go up?"

Her stage of the menopause transition is one part of the picture worth considering.

A Standard Cholesterol Panel Doesn't Always Tell the Whole Story

A routine lipid panel generally includes:

  • Total cholesterol
  • LDL cholesterol
  • HDL cholesterol
  • Triglycerides

These numbers are important and remain central to cardiovascular risk assessment.

However, depending on an individual's medical history and overall cardiovascular risk, additional markers may sometimes provide useful information.

ApoB

Apolipoprotein B (ApoB) reflects the number of atherogenic lipoprotein particles circulating in the blood.

That's different from LDL cholesterol, which measures the amount of cholesterol being carried within LDL particles.

Two people can therefore have similar LDL cholesterol levels but different numbers of atherogenic particles.

The 2026 ACC/AHA dyslipidemia guideline recognizes selective ApoB measurement as a useful tool for refining cardiovascular risk in certain patients.

Lipoprotein(a)

Lipoprotein(a), or Lp(a), is another cardiovascular risk factor that isn't included in a routine lipid panel.

Lp(a) levels are largely genetically determined and tend to remain relatively stable throughout life.

The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood to help identify individuals with increased atherosclerotic cardiovascular disease risk.

Unlike many traditional cardiovascular risk factors, lifestyle changes generally have minimal effect on the Lp(a) level itself. However, identifying an elevated Lp(a) can make aggressive management of other modifiable cardiovascular risk factors even more important.

Close-up of a clinician's hands reviewing a lipid panel blood test report on a clipboard next to blood sample tubes, clean clinical lighting, soft blue and white tones, medical

What Other Cardiometabolic Markers May Be Considered?

Cardiovascular risk isn't determined by a single laboratory value, and more testing isn't automatically better testing.

Depending on an individual's history, family history and existing risk factors, a broader evaluation may include selected measures such as:

  • Complete lipid panel
  • ApoB
  • Lipoprotein(a)
  • LDL particle number or characteristics in selected circumstances
  • Fasting glucose
  • Hemoglobin A1c
  • Additional metabolic or inflammatory markers when clinically appropriate

The goal is not to order every available test. It's to determine which information is actually useful for that individual patient and whether it changes clinical decision-making.

What About LDL Particle Size?

You may also hear about LDL particle number, particle size or small dense LDL.

Research has found associations between LDL particle characteristics and cardiovascular risk. A systematic review and meta-analysis found LDL particle number to be positively associated with cardiovascular risk, while larger LDL particle size was inversely associated with risk.

Small dense LDL has also been associated with increased atherosclerotic cardiovascular risk.

These tests are not necessary for every patient, but they can provide additional context in selected situations.

Sometimes Bloodwork Isn't Enough

For appropriately selected patients, a coronary artery calcium (CAC) score may provide additional information about cardiovascular risk.

CAC scoring uses a noncontrast CT scan to detect calcified plaque in the coronary arteries.

The 2026 ACC/AHA dyslipidemia guideline supports selective CAC scoring to help refine risk and guide treatment decisions when a person's cardiovascular risk remains uncertain.

It isn't something every woman needs.

Whether CAC testing is appropriate depends on age, overall cardiovascular risk and the clinical question being asked.

Woman in midlife, approximately 45-55 years old, calmly undergoing a CT scan in a modern clinical imaging room, wearing a hospital gown, technologist nearby, soft clinical

What Does All of This Have to Do With HRT?

Quite a bit, but this is where the conversation needs to stay nuanced.

Menopausal hormone therapy can affect lipid and other cardiometabolic markers, but HRT should not be prescribed solely for the purpose of preventing cardiovascular disease.

When considering hormone therapy, I don't want to look only at an estradiol level or a list of menopausal symptoms.

A woman's age, symptoms, medical history, time since menopause and baseline cardiovascular and metabolic health all matter.

The type, dose, route and timing of hormone therapy can matter as well.

That's why I believe hormone care should be individualized.

Hormones are one part of a much bigger health picture.

Midlife Is an Opportunity for Prevention

Warm, natural photo of a woman in her mid-40s to early 50s consulting with her healthcare provider about hormone therapy, seated in a bright, comfortable clinic room, engaged

We often talk about perimenopause and menopause primarily in terms of symptoms:

Hot flashes. Sleep disruption. Brain fog. Changes in body composition. Mood changes.

But this stage of life is also an opportunity to evaluate the health factors that may influence the next several decades.

For me, the conversation isn't simply:

"How do we make your symptoms better?"

It's also:

"What can we learn about your health now that may help you age well?"

Hormones. Metabolism. Heart health. Muscle. Sleep. Nutrition. Lifestyle.

They're connected.

And midlife gives us an important opportunity to start paying attention to all of them.

Looking for a More Individualized Approach to Midlife Health?

At Core Function Health, I take a personalized approach to hormone health, metabolic health and healthy aging.

For women considering hormone therapy, evaluation goes beyond simply checking hormone levels. Symptoms, medical history, appropriate laboratory testing and individual cardiovascular and metabolic risk all help inform the conversation.

Core Function Health is based in Seal Beach, California, serving women throughout Orange County, Long Beach, and across California.

References & Further Reading

  1. El Khoudary SR, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. PMID: 33251828. PubMed – Menopause Transition and Cardiovascular Disease Risk{target="_blank"}
  2. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. PMID: 35797481. PubMed – 2022 Hormone Therapy Position Statement{target="_blank"}
  3. Quesada JA, et al. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis. Clin Investig Arterioscler. 2023. PMID: 36522243. PubMed – Lipoprotein Particle Size and Number{target="_blank"}
  4. Krauss RM. Small dense low-density lipoprotein particles: clinically relevant? Curr Opin Lipidol. 2022. PMID: 35276699. PubMed – Small Dense LDL Particles{target="_blank"}
  5. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. PubMed – 2026 Guideline on the Management of Dyslipidemia

Medical Disclaimer

This article is for educational and informational purposes only and is not intended to provide medical advice, establish a clinician-patient relationship, or substitute for individualized evaluation, diagnosis or treatment by a qualified healthcare professional. Cardiovascular risk assessment, laboratory testing, imaging and hormone therapy should be individualized based on personal medical history, risk factors and clinical evaluation. If you have questions or concerns about your health, please consult your healthcare professional.